Despite the limitations of our study as a single-center study of an unselected EGFR mutant lung cancer cohort, this consistent proportion of MET amplification as determinant of resistance makes it reasonable to find the enriched population to evaluate. This evidence concerns the gene EGFR and lung carcinoma.